Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer

The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and should have continued therapy with paclitaxel as the discretion of the investigator, and to evaluate the frequency and the severity of observed adverse reactions in treated subjects

Inclusion Criteria:

• Subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and should have continued therapy with paclitaxel as the discretion of the investigator